Aratana Therapeutics postpones $51 million IPO

By Renaissance Capital,

Shutterstock photo

Aratana Therapeutics, which is developing medications for cats and dogs based on therapies for humans, postponed its IPO on Tuesday citing poor market conditions. The Kansas City, KS-based company was founded in 2010 and had expected to raise $51 million in its IPO by offering 4.3 million shares at a $11-$13 range. Stifel and Lazard Capital Markets were set to be the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: PETX

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by